Cholestyramine Light (cholestyramine) NDC 51224-009

NDC codes

FDA NDC Directory

Product NDC (as listed)51224-009Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51224-0009Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51224-009-10	51224000910	201.6 g in 1 CAN (51224-009-10)Marketed from Nov 12, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cholestyramine Light
Generic name (nonproprietary): cholestyramine
Active ingredients: Cholestyramine — 4 g/4.8g
Dosage form: Powder, For suspension
Route: Oral
Labeler: TAGI Pharma, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209599
Marketing start: Nov 12, 2020
Marketing end: Jan 31, 2027
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 51224-009_fb8b0e9c-1750-4016-95c7-d7a49e09d463SPL ID fb8b0e9c-1750-4016-95c7-d7a49e09d463SPL set ID eb85a2c8-cdc3-48bb-844d-e220ae3701a0RxCUI 1801279UNII 4B33BGI082
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451224000910 followed by a unit qualifier and the quantity

Package 51224-0009-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 17, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE 1) Cholestyramine for oral suspension USP, light is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension USP, light may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular dise…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 209599

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209599
Product	Strength	Form · route	Labeler	Product NDC
Cholestyramine	Cholestyramine 4 g/4.8g	Powder, For suspensionOral	Precision Dose, Inc.	68094-906